IP Library Granted Patent US 10,434,052
Granted Patent B2
US 10,434,052 · App. 15/706,908 · Granted Oct 8, 2019

Gamma-diketones for treatment and prevention of aging skin and wrinkles

Inventors: John Hood (San Diego, CA); Sunil Kumar KC (San Diego, CA); Osman Kibar (La Jolla, CA); Charlene F. Barroga (San Diego, CA)
Assignee: Samumed, LLC
A61K8/4986A61K8/35A61K8/41A61K8/49A61K8/492A61K8/494A61K8/498A61K8/4913A61K8/4926A61K8/4946A61K8/4953A61K8/4973A61K8/69A61K8/70A61Q19/007A61Q19/02A61Q19/08A61K2800/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,434,052
App. No.
15/706,908
Granted
Oct 8, 2019
Kind
B2
Abstract

The present disclosure relates to compounds having the following structure: or a dermatologically acceptable salt thereof, and cosmetic or dermopharmaceutical compositions comprising the same, and methods for using the compounds or compositions for treating, protecting, and/or improving the condition and/or aesthetic appearance of skin, for example, treating, preventing, ameliorating, reducing and/or eliminating fine lines and/or wrinkles of skin, or improving the appearance of fine lines and/or or wrinkles of skin comprising application of the compounds or compositions disclosed.

Claims (44)

1. A method for improving the aesthetic appearance of a subject's skin, the method comprising administering to the subject an effective amount of a compound of Formula II, or a dermatologically acceptable salt thereof:

wherein:

Ring C is a 5-6 membered heteroaryl, with the proviso that a carbon atom on the ring is attached to the carbonyl carbon;

Ring D is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, with the proviso that a carbon atom on the ring is attached to the carbonyl carbon;

R 4 is a substituent attached to Ring C and is independently selected at each occurrence from the group consisting of unsubstituted —C 1-6 alkyl, —C 1-3 haloalkyl, halide, —OR 6 , and CN;

R 5 is a substituent attached to Ring D and is independently selected at each occurrence from the group consisting of unsubstituted —C 1-6 alkyl, —CH 2 OH, —CH 2 N(R 6b ) 2 , —C 1-3 haloalkyl, halide, —OR 6 , and CN;

each R 6 is independently selected from the group consisting of H, unsubstituted —C 1-6 alkyl, and —C 1-3 haloalkyl;

each R 6b is independently selected from the group consisting of H and unsubstituted —C 1-3 alkyl;

each q is 0 to 4; and

each p is 0 to 5.

2. The method of claim 1 , wherein the compound of Formula II is selected from the group consisting of:

or a dermatologically acceptable salt thereof.

3. The method of claim 1 , wherein the compound of Formula II is selected from the group consisting of:

or a dermatologically acceptable salt thereof.

4. The method of claim 1 , wherein the compound of Formula II is selected from the group consisting of:

or a dermatologically acceptable salt thereof.

5. The method of claim 1 , wherein the compound of Formula II is selected from the group consisting of:

or a dermatologically acceptable salt thereof.

6. The method of claim 1 , wherein the compound of Formula II is selected from the group consisting of:

or a dermatologically acceptable salt thereof.

7. The method of claim 1 , wherein the compound of Formula II is selected from the group consisting of:

or a dermatologically acceptable salt thereof.

8. The method of claim 1 , wherein the compound of Formula II is selected from the group consisting of:

or a dermatologically acceptable salt thereof.

9. The method of claim 1 , wherein the compound of Formula II is selected from the group consisting of:

or a dermatologically acceptable salt thereof.

10. A method for improving the aesthetic appearance of a subject's skin, the method comprising administering to skin an effective amount of a cosmetic or dermopharmaceutical composition comprising a compound according to Formula II, or a dermatologically acceptable salt thereof;

wherein:

Ring C is a 5-6 membered heteroaryl, with the proviso that a carbon atom on the ring is attached to the carbonyl carbon;

Ring D is selected from the group consisting of phenyl and a 5-6 membered heteroaryl, with the proviso that a carbon atom on the ring is attached to the carbonyl carbon;

R 4 is a substituent attached to Ring C and is independently selected at each occurrence from the group consisting of unsubstituted —C 1-6 alkyl, —C 1-3 haloalkyl, halide, —OR 6 , and CN;

R 5 is a substituent attached to Ring D and is independently selected at each occurrence from the group consisting of unsubstituted —C 1-6 alkyl, —CH 2 OH, —CH 2 N(R 6b ) 2 , —C 1-3 haloalkyl, halide, —OR 6 , and CN;

each R 6 is independently selected from the group consisting of H, unsubstituted —C 1-6 alkyl, and —C 1-3 haloalkyl;

each R 6b is independently selected from the group consisting of H and unsubstituted —C 1-3 alkyl;

each q is 0 to 4; and

each p is 0 to 5.

11. The method of claim 1 , wherein the improvement in aesthetic appearance is improvement in one or more of skin tone, radiance, clarity, tautness, skin firmness, plumpness, suppleness, softness, skin texture, skin texturization and moisturization, appearance of skin contours, appearance of hollow cheeks, appearance of sunken, baggy, or dark circles under eyes, skin luster, brightness, skin thickness, and skin elasticity and/or resiliency.

12. The method of claim 1 , wherein the improvement in aesthetic appearance is the reduction of fine lines or wrinkles.

13. The method of claim 1 , wherein the improvement in aesthetic appearance is the improvement in procollagen and/or collagen production.

14. The method of claim 1 , wherein the compound is administered as a cosmetic or dermopharmaceutical composition.

15. The method according to claim 14 , wherein the cosmetic or dermopharmaceutical composition is a topical composition.

16. The method according to claim 14 , wherein the cosmetic composition is intended for use as a non-therapeutic treatment.

17. The method according to claim 1 , wherein the subject is human.

18. The method according to claim 10 , wherein the subject is human.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Mar 12, 2026
From: TMF GROUP NEW YORK, LLC, NOT INDIVIDUALLY BUT SOLELY AS COLLATERAL AGENT
To: BIOSPLICE THERAPEUTICS, INC.
Reel/Frame 075109/0434 →
SECURITY INTEREST Recorded Sep 14, 2022
From: BIOSPLICE THERAPEUTICS, INC.
To: VICKERS VENTURE FUND VI PTE. LTD.; VICKERS VENTURE FUND VI (PLAN) PTE. LTD.; VICKERS-SPLICE CO-INVESTMENT LLC; MED-PATHWAYS II LIMITED
Reel/Frame 061433/0786 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 23, 2021
From: SAMUMED, LLC
To: BIOSPLICE THERAPEUTICS, INC.
Reel/Frame 055693/0809 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 4, 2019
From: HOOD, JOHN; KC, SUNIL KUMAR; KIBAR, OSMAN; BARROGA, CHARLENE F.
To: SAMUMED, LLC
Reel/Frame 048799/0440 →
Continuity (3)
Division 14831456 · Aug 20, 2015
Provisional Application 62039786 · Aug 20, 2014
Related Publication 20180193244A1 · Jul 12, 2018
Cited By (1)
US 12,194,120